PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma

Table 1

Association between PLEKHA4 expression and clinicopathologic features in the validation cohort.

Characteristic	Low expression of PLEKHA4	High expression of PLEKHA4
	348	348
Age, (%)			<0.001
< =60	316 (45.4%)	237 (34.1%)
> 60	32 (4.6%)	111 (15.9%)
Gender, (%)			0.491
Female	154 (22.1%)	144 (20.7%)
Male	194 (27.9%)	204 (29.3%)
WHO grade, (%)			<0.001
G2	177 (27.9%)	47 (7.4%)
G3	116 (18.3%)	127 (20%)
G4	16 (2.5%)	152 (23.9%)
IDH status, (%)			<0.001
Mut	319 (46.5%)	121 (17.6%)
WT	26 (3.8%)	220 (32.1%)
1p/19q codeletion, (%)			<0.001
Codel	159 (23.1%)	12 (1.7%)
Noncodel	187 (27.1%)	331 (48%)
Histological type, (%)			<0.001
Astrocytoma	73 (10.5%)	122 (17.5%)
Oligoastrocytoma	92 (13.2%)	42 (6%)
Oligodendroglioma	167 (24%)	32 (4.6%)
Glioblastoma	16 (2.3%)	152 (21.8%)